Fig 5. CCX559 dose-dependently suppressed MC38-hPD-L1 tumor growth, induced tumor regression and reduced tumor cell surface PD-L1 levels.

CCX559, MEDI4736, and control treatments were started in C57BL/6 mice after tumor formation (>30 mm³) on day 11 post MC38-hPD-L1 cell inoculation: CCX559 was dosed orally once daily, and MEDI4736 was dosed intraperitoneally every 5 days for 3 doses. (A) CCX559 (10 and 30 mg/kg) and MEDI4736 significantly reduced average tumor volumes at day 35, compared to their respective controls. (B) The number of mice with a complete response, i.e. no detectable tumor remaining, is shown for each group (n = 10). (C) The percent of CD45- cells in dissociated tumors with detectable cell surface hPD-L1 was reduced by CCX559 and MEDI4736 treatment. (D) Plasma CCX559 concentrations were measured 24 hours after the last dose. All data are represented as mean ± SD, ***denotes p < 0.001, ****denotes p < 0.0001. Statistical analyses for the study arms were the same as Fig 4.